Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post by Viz.ai, adding:
“The Unseen Revolution: How Artificial Intelligence Is Redefining Cancer Care-featured in this week’s NEJM AI:
Despite major therapeutic advances, cancer care remains limited by episodic monitoring that misses the continuous, unseen dynamics of disease and treatment. Artificial intelligence offers the ability to detect early signs of toxicity, resistance, and deterioration by integrating data across genomics, imaging, wearables, and patient-reported outcomes. This transformation demands organizational and cultural change — moving from retrospective observation to proactive, real-time care. Harnessed responsibly, AI represents not just a technological evolution but a moral imperative to deliver more intelligent, equitable, and anticipatory cancer care.
The transformation of cancer care through AI represents both an unprecedented opportunity and a profound responsibility. The patients we serve today deserve nothing less than our commitment to harnessing every available tool to improve their outcomes. AI represents perhaps the most powerful tool we have ever possessed. Whether we use it wisely and equitably will determine not just the future of cancer care, but our worthiness of the trust patients place in us. The revolution is already underway.
The question is not whether it will happen, but whether we will lead it or be swept along by it. For the sake of our patients, we must choose to lead.
Thanks to Rebecca Maniago, Carolyn Jones, and Anne Hellie for inviting me to pen this feature, and for helping put together such a thoughtful piece.”
Quoting Viz.ai‘s post:
“A new NEJM AI feature by Douglas Flora and Viz.ai’s Rebecca Maniago, PharmD, BCOP, explores a critical evolution in oncology. As precision medicine advances, so must the way we monitor patients. The traditional episodic model simply can’t capture the subtle, continuous changes occurring between clinic visits.
Their article makes the case that AI is no longer optional — it’s foundational. AI excels at the capabilities modern oncology urgently needs: continuous pattern recognition, the ability to integrate complex multi-modal data, and early detection of emerging issues before they escalate.
This shift toward precision monitoring represents a meaningful step in improving outcomes and delivering anticipatory, patient-centered care.
More posts featuring Douglas Flora on OncoDaily.